Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENSKYCE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Induction and maintenance of sedation in adult patients undergoing diagnostic or therapeutic procedures
Prevention of pregnancy (FDA-approved)
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Fospropofol is rapidly converted to propofol, phosphate, and formaldehyde by alkaline phosphatases (primarily in liver and plasma). Propofol is then metabolized in the liver via glucuronidation (UGT1A9) and hydroxylation (CYP2B6, CYP2C9) to inactive metabolites.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
95% bound to albumin
~99% bound to serum albumin and sex hormone-binding globulin.
0.25 L/kg (low, indicates minimal tissue distribution)
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 80% (with interindividual variability)
Oral: ~70% due to first-pass metabolism.
Cr Cl 30-79 m L/min: No adjustment. Cr Cl 15-29 m L/min: Reduce dose to 1 g IV every 8 hours. Cr Cl <15 m L/min: Use 1 g IV every 24 hours; consider alternative therapy.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 1.5 g IV every 8 hours. Child-Pugh C: Use 1 g IV every 12 hours; clinical monitoring recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
WARNING: RISK OF RESPIRATORY DEPRESSION AND NEED FOR RESUSCITATION EQUIPMENT. ENSKYCE should be administered only by personnel trained in the administration of general anesthesia and management of airway emergencies. Resuscitation equipment and drugs must be immediately available. Because of the potential for respiratory depression, patients must be continuously monitored for respiratory function.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Respiratory depression and apnea,Hypotension and bradycardia,Must only be administered by trained anesthesia personnel,Risk of propofol infusion syndrome (with prolonged use),May cause hypotension; correct hypovolemia before administration,Use caution in elderly or debilitated patients,May cause pain on injection,Monitoring of vital signs required
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, soy products, or peanuts (due to excipients),Patients with severe hepatic impairment or lipid metabolism disorders (relative)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid high-fat, fried, or spicy foods as they may exacerbate gastrointestinal adverse effects; take with or without food; maintain adequate fluid intake to reduce constipation risk; no specific food-drug interactions but alcohol may increase hypoglycemic risk when combined with other antidiabetic drugs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs risk. Second and third trimester: no known fetal risks, but limited data.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
No data on secretion in human milk; M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infants. Weigh benefits against risks.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No established dose adjustments for pregnancy. Pharmacokinetic changes (increased volume of distribution, enhanced clearance) may reduce drug exposure; monitor clinical response and consider dose titration if efficacy wanes.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Start with 2.5 mg once weekly, escalate by 2.5 mg increments every 4 weeks to minimize gastrointestinal intolerance; monitor renal function (e GFR required before initiation); if e GFR <30 m L/min/1.73 m², use 0.5 mg initiation and titrate slowly; switch from subcutaneous semaglutide to ENSKYCE requires same dose but monitor for 4 weeks for GI side effects; thyroid C-cell tumor risk requires baseline calcitonin; do not use in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take exactly as prescribed; do not change dose or frequency without consulting doctor.,Visual injection aids: inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly.,Most common side effects are nausea, vomiting, diarrhea, and constipation; these may decrease over time.,Avoid alcohol and high-fat meals as they may increase gastrointestinal side effects.,Report symptoms of thyroid tumors: lump in neck, difficulty swallowing, hoarseness.,If severely vomiting or unable to eat/drink, seek medical attention to prevent dehydration and kidney injury.,Do not share pens; store in refrigerator between 36-46°F (2-8°C); protect from light.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENSKYCE vs AFIRMELLE, answered by our medical review team.
ENSKYCE is a Oral Contraceptive that works by ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENSKYCE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENSKYCE is: 2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENSKYCE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENSKYCE is classified as Category C. No human data available; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded in first trimester; avoid use unless benefit outweighs ris. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.